Your browser doesn't support javascript.
loading
Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.
Wang, Ruoyu; Lu, Justin Y; Herbert, Deanna; Lieberman, Jeffrey A; Meltzer, Herbert Y; Tiwari, Arun K; Remington, Gary; Kennedy, James L; Zai, Clement C.
Afiliação
  • Wang R; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Lu JY; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Herbert D; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Lieberman JA; Columbia University, New York State Psychiatric Institute, New York City, New York, USA.
  • Meltzer HY; Psychiatry and Behavioral Sciences, Pharmacology and Physiology, Chemistry of Life Processes Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Tiwari AK; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Remington G; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Kennedy JL; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Zai CC; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Hum Psychopharmacol ; 39(4): e2898, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38676936
ABSTRACT

OBJECTIVES:

The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Component C4 gene in the HLA region. In this study, we explored the HLA region further by examining two previously identified schizophrenia-associated HLA-region single-nucleotide polymorphisms (SNPs), namely rs13194504 and rs210133.

METHODS:

The SNPs rs13194504 and rs210133 were tested for association with the occurrence and severity of TD in a sample of 172 schizophrenia patients who were recruited for four studies from three different clinical sites in Canada and USA.

RESULTS:

The rs13194504 AA genotype was associated with decreased severity for TD as measured by Abnormal Involuntary Movement Scale (AIMS) scores (p = 0.047) but not for TD occurrence. SNP rs210133 was not significantly associated with either TD occurrence or AIMS scores.

CONCLUSION:

Our findings suggest that the rs13194504 AA genotype may play a role in TD severity, while SNP rs210133 may not have a major role in the risk or severity of TD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Polimorfismo de Nucleotídeo Único / Discinesia Tardia Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Polimorfismo de Nucleotídeo Único / Discinesia Tardia Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article